Other exciting candidates in Novavax's pipeline include a potential vaccine against malaria in a phase 2b study and an investigational Ebola vaccine in a phase 1 study. Of course, Novavax's most important program other than NVX-CoV2373 is arguably its potential flu vaccine, NanoFlu. While this candidate took a back seat once the pandemic started, Novavax reported positive results from a late-stage study for NanoFlu as far back as March 2020.